Loading...
•
Dec 31, 2021
Kala Bio Q4 2021 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2021.
Key Takeaways
Kala Pharmaceuticals reported Q4 2021 net product revenues of $1.9 million, with EYSUVIS sales at $1.2 million and INVELTYS sales at $0.7 million. The company had cash and cash equivalents of $92.1 million as of December 31, 2021.
EYSUVIS prescriptions increased by 21% quarter-over-quarter in Q4 2021.
Coverage secured for EYSUVIS includes 118 million commercial lives and 7.1 million Medicare lives.
KPI-012 Phase 1b clinical data accepted for presentation at ARVO.
Phase 2/3 clinical trial of KPI-012 expected to start in Q4 2022.
Forward Guidance
Kala anticipates that its cash resources as of December 31, 2021, together with anticipated revenue from EYSUVIS and INVELTYS, will enable it to fund its operations into the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...